Gapping up
In reaction to earnings/guidance:
In reaction to earnings/guidance:
- ABM +7.1%, PLAB +5%, CGNT +4.3%, REVG +3.9%
Other news:
- CCCC +15% (announces CFT7455 Phase 1 trial data)
- LFMD +12.5% (LifeMD and Medifast (MED) partner to offer transformative weight management solution)
- VSTM +10.4% (initiation of a confirmatory phase 3 trial of avutometinib and defactinib in recurrent low-grade serous ovarian cancer)
- VRTX +7.2% (Results From Phase 2 Study of VX-548 for the Treatment of Painful Diabetic Peripheral Neuropathy)
- CRBU +5.8% (provides regulatory update on CB-010 with Phase 3 trial initiation expected by YE24)
- TTWO +3.4% (Take-Two Interactive Software (TTWO) will be added to the Nasdaq-100 Index)
- BBAI +3% (awarded $17.9 mln extension on Phase 2 of U.S. Army GFIM OTA)
- WSR +2.7% (Board of Trustees responds to proposal from Bruce Schanzer / Erez Asset Management)
- COMP +2.6% (COO to depart; COO role to be eliminated)
- HCM +2.6% (completed enrollment of a Phase II/III Trial of Fruquintinib in combination with Sintilimab for advanced renal cell carcinoma in China; announces continued inclusion of ELUNATE and SULANDA in the National Reimbursement Drug List in China at current terms)
- TTC +2.4% (increases dividend)
- VERX +2.3% (Offers to acquire Pagero)
- MED +2.1% (initiates business transformation by entering the medically supported weight loss market through collaboration with LifeMD (LFMD); MED to discontinue the company's quarterly cash dividend effective immediately)
- RPT +1.9% (RPT shareholders approve previously announced merger with KIM)
- ZLAB +1.7% (First Listing of VYVGART (efgartigimod alfa injection) and Other Updates in China's National Reimbursement Drug List)
- VET +1.6% (announces 2024 budget and updated return of capital framework; increases dividend)
- ATS +1.5% (announces normal course issuer bid)
- HBNC +1.3% (executes a balance sheet repositioning)
- ABNB +1.2% (provided an update on the Italian tax authorities' tax assessment of 779 million euros on Airbnb's Irish subsidiary)
Analyst comments:
- ALLY +1.3% (upgraded to Equal-Weight from Underweight at Morgan Stanley)
- QTWO +1.2% (upgraded to Neutral from Underweight at Piper Sandler)
- OPEN +0.6% (upgraded to Mkt Perform from Underperform at Keefe Bruyette)